Navigation

Kalliga

  • Generic Name: desogestrel and ethinyl estradiol tablets
  • Brand Name: Kalliga

Kalliga (Desogestrel And Ethinyl Estradiol Tablets) side effects drug center

 

PROFESSIONAL

SIDE EFFECTS

Kalliga Side Effects Center

Kalliga (desogestrel and ethinyl estradiol tablets 0.15 mg/0.03 mg) is an oral contraceptive regimen indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Kalliga is available in generic form. Common side effects of Kalliga include:

Do not use Kalliga if you smoke cigarettes and are over 35 years old.

The dosage of Kalliga for the initial cycle of therapy is one white to off-white “active” tablet administered daily from the 1st day through the 21st day of the menstrual cycle, counting the first day of menstrual flow as "Day 1", then one green “reminder” tablet daily for 7 days. After 28 tablets have been taken, a new course is started. To achieve maximum contraceptive effectiveness, Kalliga must be taken exactly as directed and at intervals not exceeding 24 hours. Kalliga may interact with seizure medicines, aprepitant, barbiturates, bosentan, colesevelam, griseofulvin, HIV medicines, non nucleoside reverse transcriptase inhibitors (NNRTIs), rifampin, rifabutin, St. John's wort, acetaminophen, ascorbic acid, itraconazole, ketoconazole, voriconazole, fluconazole, statin drugs, etravirine, and thyroid replacement therapy. Tell your doctor all medications and supplements you use. Kalliga is not recommended for use during pregnancy. Small amounts of oral contraceptives such as Kalliga pass into breast milk and can cause adverse effects on nursing infants. Oral contraceptives may decrease the quantity and quality of breast milk. Breastfeeding while using Kalliga is not recommended.

Our Kalliga (desogestrel and ethinyl estradiol tablets 0.15 mg/0.03 mg) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

 

Kalliga Professional Information

SIDE EFFECTS

An increased risk of the following serious adverse reactions has been associated with the use of oral contraceptives (see WARNINGS).

There is evidence of an association between the following conditions and the use of oral contraceptives:

  • Mesenteric thrombosis
  • Retinal thrombosis

The following adverse reactions have been reported in patients receiving oral contraceptives and are believed to be drug-related:

  • Nausea
  • Vomiting
  • Gastrointestinal symptoms (such as abdominal cramps and bloating)
  • Breakthrough bleeding
  • Spotting
  • Change in menstrual flow
  • Amenorrhea
  • Temporary infertility after discontinuation of treatment
  • Edema
  • Melasma which may persist
  • Breast changes: tenderness, enlargement, secretion
  • Change in weight (increase or decrease)
  • Change in cervical erosion and secretion
  • Diminution in lactation when given immediately postpartum
  • Cholestatic jaundice
  • Migraine
  • Allergic reaction, including rash, urticaria, and angioedema
  • Mental depression
  • Reduced tolerance to carbohydrates
  • Vaginal candidiasis
  • Change in corneal curvature (steepening)
  • Intolerance to contact lenses

The following adverse reactions have been reported in users of oral contraceptives and a causal association has been neither confirmed nor refuted:

Read the entire FDA prescribing information for Kalliga (Desogestrel And Ethinyl Estradiol Tablets)

&Copy; Kalliga Patient Information is supplied by Cerner Multum, Inc. and Kalliga Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.